Citations

Showing 10 of 108083 citations.

CD2-iCre mice reveal a role for ABCB7 in B cell development and bone marrow homeostasis
Lehrke, Michael Jonathan , McCue, Shaylene , Rajcula, Matthew, Shapiro, Michael J. , Shapiro, Michael, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 53.17-53.17

10.4049/jimmunol.202.supp.53.17 Get It

Abstract ABCB7 is a mitochondrial transporter that exports iron-sulfur (Fe-S) cluster intermediates from the mitochondria to the cytoplasm. Using CD2-iCre ABCB7 cKO mice, we found ABCB7 is required for early B cell development. These mice have a severe block in pro-B cell development at the Fr. C to Fr. C′ transition, with reduced expression of intracellular μ and pre-BCR. CD19-cre and CD23-cre ABCB7 cKO mice have normal B cell development and peripheral B cell populations, indicating ABCB7 is required only during early B cell development. We observed reduced expression of Runx1, Ikaros, Foxo1, E47 (E2A), and Pax5 in CD2-iCre ABCB7 cKO pro-B cells. Interestingly, we also observed decreased BACH2 expression, which indicates elevated heme synthesis is occurring in the absence of ABCB7. We hypothesize that in the absence of ABCB7, developing B cells enhance heme synthesis to dispose of accumulating mitochondrial iron. Using a hen egg lysozyme BCR transgene, we were able to rescue B cell development in CD2-iCre ABCB7 cKO mice. Intriguingly, at the age of 5–8 weeks old, CD2-iCre ABCB7 cKO mice become lethargic and hunched. CBCs reveal an increase in peripheral blood neutrophils. Both the spleen and bone marrow become highly infiltrated by CD11b+Ly6Glow/+Ly6C− cells that are immature and mature neutrophils. As other knockout mice with pro-B cell blocks do not have neutrophilia, we considered if increased iron or heme is responsible for our observation. As heme can stimulate TLR4, we propose that excess heme from developing ABCB7-deficent B cells activates macrophages. In support of this, hemin induced GM-CSF production in BMDM cultures. We are currently exploring the mechanism by which excess heme production can stimulate the production of neutrophils.
Hoxa9 silencing of p16 ink4a is essential for murine lymphopoiesis
Medina, Kay L. , Gwin, Kimberly

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 53.20-53.20

10.4049/jimmunol.202.supp.53.20 Get It

Abstract The homeo-domain transcription factor Hoxa9 is required for normal B and T lymphocyte development in bone marrow (BM) and thymus, respectively. Here we show that Hoxa9-deficiency is accompanied by increased expression of the cdkn2a tumor suppressor locus that encodes the cell cycle inhibitor p16Ink4a. Furthermore, we found that somatic deletion of p16Ink4a is sufficient to rescue the B and T cell progenitor deficiencies, as well as the BM lymphoid progenitor pools, in hoxa9−/− mice. In contrast, the hematopoietic stem cell (HSC) and multipotential progenitor (MPP) abnormalities characteristic of Hoxa9-deficient mice were not corrected by loss of p16Ink4a. These new data reveal that Hoxa9 repression of p16ink4a is essential for lymphoid lineage development in BM and thymus. Importantly, they highlight distinct functions for Hoxa9 in regulation of primitive hematopoietic progenitors versus those committed to the B or T cell fates.
Oral tolerance to peanut allergy is mediated by CTLA-4-positive regulatory T cells
Iijima, Koji, Kobayshi, Takao, Krempski, James , Kobayshi, Takao, Kita, Hirohito

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 55.2-55.2

10.4049/jimmunol.202.supp.55.2 Get It

Abstract Peanut allergies are life-long diseases that cause severe anaphylactic responses to affected individuals. Oral ingestion of peanut products prevents infants from developing peanut allergy. However, little information is currently available regarding the immunologic mechanisms for this protection. Therefore, the goal of this project was to establish an oral tolerance model to peanut allergy in mice and to determine the immunologic mechanisms. Naïve BALB/c mice that were exposed intranasally (i.n.) to peanut flour (PNf) developed peanut allergy as demonstrated by increased serum levels of IgE antibody as well as acute anaphylactic response when challenged with peanut extract. When mice were fed peanut butter (PNB) prior to i.n PNf exposure, they were protected from developing peanut allergy; these mice showed decreased serum levels of IgE antibody and lacked anaphylactic response. T follicular helper (Tfh) cells and germinal center (GC) B cells were decreased in lung draining lymph nodes of mice fed PNB. Furthermore, scRNSseq revealed 2 distinct CD4+ T cell subpopulations that are increased in those protected mice. CTLA-4, a checkpoint molecule, was highly expressed in one of these subpopulations. Systemic administration of a CTLA-4 blocking antibody to mice fed PNB increased the numbers of Tfh cells and GC B cells and increased serum levels of IgE antibody. Finally, anti-CTLA-4 reversed the clinical efficacy of oral PNB administration, resulting in manifestation of acute anaphylaxis when challenged with peanut extract. Thus, oral administration of peanut product(s) prevents development of peanut allergy in mice. CTLA4+CD4+ T cells likely play a pivotal role in this process by regulating the development of Tfh cells.
The function of the circulating innate lymphoid cells is dysregulated in patients with mild asthma
Bachman, Kay, Drake, Li Y. , Kita, Hirohito

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 119.27-119.27

10.4049/jimmunol.202.supp.119.27 Get It

Abstract Group 2 innate lymphoid cells (ILC2s) play crucial roles in type 2 immunity in the lungs and in the development of asthma pathology. While ILC2s are residents in mucosal tissues, they also circulate in peripheral blood. Evidence suggests that blood ILC2s can be used as an indirect but useful biomarker to monitor the activity of ILC2s in mucosal tissues, such as the lungs. To investigate both the innate immune response and the corresponding ILC2 cell levels in the peripheral blood of asthma patients, we collected peripheral blood mononuclear cells (PBMCs) from 11 adult patients with mild asthma (MA) and 12 adult healthy control (HC) subjects. The innate type 2 immune responses of PBMCs and the number of blood ILC2s were examined by in vitro culture and flow cytometry. We found that in response to IL-25 or IL-33 stimulation, PBMCs from MA subjects produced significant higher levels of IL-5 than PBMCs from HC subjects. However, there were no significant differences in ILC2 numbers or proportions between MA and HC groups. These results suggest that the function, but not the number, of blood ILC2s may serve as a general biomarker for human asthma.
A novel mechanism of innate immune dysfunction in untreated Chronic Lymphocytic Leukemia.
Mikkelson, Molly G., Gwin, Kimberly, Secreto, Charla, Ding, Wei , Medina, Kay L. , Manso, Bryce A. , Zhang, Henan , Ding, Wei, Parikh, Sameer A. , Kay, Neil E.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 200 | Issue: Supplement_1 | Pages: 178.18-178.18

10.4049/jimmunol.200.supp.178.18 Get It

Abstract The consequences of immune dysfunction in B-Chronic Lymphocytic Leukemia (CLL) likely relate to the incidence of serious recurrent infections and second malignancies that plague CLL patients. The known immune abnormalities are not able to consistently explain these complications and it is not easy to correct their immune status. Here, we report bone marrow (BM) hematopoietic dysfunction in early and late stage untreated CLL patients. We found reduced functional capacity of hematopoietic progenitors in BM using colony forming unit assays and flow cytometry revealed significant reductions in frequencies of hematopoietic stem and progenitor cell (HSPC) populations. Consistent with the reduction in HSPCs, monocytes and natural killer cells in BM were reduced and the reduction in BM was recapitulated in blood. Finally, we report imbalances in protein levels of the transcriptional regulators HIF-1α, PU.1, and GATA-2 in CLL patient BM, providing molecular insight into the basis of HSPC dysfunction. Importantly, PU.1 and GATA-2 were rapidly increased when healthy HSPCs were exposed in vitro to TNFα, a cytokine constitutively produced by CLL B cells. Together, these findings reveal BM hematopoietic dysfunction in untreated CLL patients, adding to the complex immunodeficiency state of these patients and the reduced capacity of the innate immune system.
Brain-Thymus communication as a novel immunosuppressive mechanism in the GL261 model of Glioblastoma
Khadka, Roman H., Malo, Courtney S. , Desai, Nidhi , Johnson, Aaron J. , Ayasoufi, Katayoun , Jin, Fang , Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 200 | Issue: Supplement_1 | Pages: 178.43-178.43

10.4049/jimmunol.200.supp.178.43 Get It

Abstract Glioblastoma multiforme (GBM) is incurable and among the most lethal of cancers. Immunotherapy for GBM is hampered by the fact that GBM patients are severely immunosuppressed with dangerously low T cell counts. Importantly, immunotherapy for GBM will be ineffective without defining the mechanism of immunosuppression. Given that GBM does not metastasize, we investigated the possibility of neuro-immune interactions using the GL261 glioma model in C57BL/6 mice. C57BL/6 mice harboring GL261 gliomas have abnormal thymuses which are acutely and significantly involuted compared to healthy control mice. Glioma bearing mice also have significant thymic atrophy which increases with tumor burden. Further structural analysis of the thymus in glioma bearing mice revealed disrupted thymic epithelial cells and reduced EPCAM+ cell expression of MHC II. Thymic subsets in tumor bearing mice were also developmentally skewed with increased generation of single positive T cells and a block at double negative 2 (DN2) to DN3 transition. Peripherally, MHCII expression was also significantly decreased in blood derived cells in glioma bearing mice. This correlated with an overall reduction in total CD4 T cell numbers. The results of this study demonstrate the GL261 model is recapitulating the immune suppression observed in GBM patients. These results also support the presence of a brain-thymus interaction that could negatively impact the development of immunotherapy strategies to treat GBM.
GRK2 transactivation of CXCR4 is required for TCR-mediated TCR-CXCR4 complex formation
Dinkel, Brittney A., Rollins, Meagan R. , Medlyn, Michael J. , Kremer, Kimberly N. , Hedin, Karen E.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 200 | Issue: Supplement_1 | Pages: 112.7-112.7

10.4049/jimmunol.200.supp.112.7 Get It

Abstract T cell cytokine production was recently shown to depend not only on the T cell antigen receptor (TCR), but also on the chemokine receptor CXCR4. Our lab recently published that stimulation of the TCR results in the TCR associating with and transactivating CXCR4, which, in turn, activates a PREX-1/Rac-1 pathway that stabilizes cytokine mRNA. This pathway therefore normally significantly increases IL-2, IL-4, and IL-10 production by activated T cells. Here, we further characterize the molecular mechanisms responsible for the first step of this pathway: TCR-mediated TCR-CXCR4 complex formation. First, we used FRET and proximity ligation assay (PLA) to define the required structural motifs of CXCR4, showing that this pathway requires the CXCR4 cytoplasmic tail domain and phosphorylation of CXCR4-S339. Second, we showed that TCR-induced TCR-CXCR4 complex formation requires TCR-induced activity of Src family and ZAP-70 tyrosine kinases, as well as one or more Ser/Thre kinases. Third, we found that the G protein-coupled receptor kinase-2 (GRK2) is required both for TCR-induced phosphorylation of CXCR4-S339 and for the formation of TCR-CXCR4 complexes. Finally, we found that GRK2 is required for robust IL-2, IL-4, and IL-10 cytokine secretion by normal human T cells. Together these results identify a novel role for TCR-induced GRK-2 in inducing the TCR-CXCR4 complex formation that subsequently signals to increase TCR-mediated cytokine production. Targeting GRK2 or other mechanisms required for TCR-induced TCR-CXCR4 formation may therefore be therapeutically useful for limiting production of T cell cytokines in humans, for example, during graft versus host disease or immunotherapy.
Too Many B cells, When Food Fights Back, and Hacking T cells: The effective use of case studies to teach methods in an undergraduate Immunology course.
Dinkel, Brittney A., Walser-Kuntz, Debby

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 200 | Issue: Supplement_1 | Pages: 113.5-113.5

10.4049/jimmunol.200.supp.113.5 Get It

Abstract The rapidly changing nature of immunology makes it a challenging course for both undergraduate students and faculty. A teaching approach that incorporates essential immunological techniques and an introduction to the primary literature helps undergraduates navigate the discipline and remain current. Case studies are an effective active learning approach that provide real world examples to engage undergraduates and an opportunity for hands on problem solving, data analysis, and critical thinking as students must consider outcomes and consequences. Although case studies that explore clinical connections already exist for undergraduates, they do not include key techniques or provide experience working with the primary literature. We have developed several case studies to help undergraduate immunology students understand and analyze data involving: flow cytometry, CRISPR/Cas, CAR T cells, and ELISAs. The case studies 1) introduce students to techniques and methods they may not have access to in their laboratory courses due to the lack of appropriate instruments or the cost of reagents, 2) build on difficult concepts covered in the course, and 3) incorporate figures from papers that challenge students to apply what they have learned. Assessment of student learning includes in-class quizzes and small group responses to data analysis questions, the use of "clickers"/personal response system, and related exam questions. Students self-report that the case studies are a highly effective teaching method that allow them to both reinforce their understanding of the course material and apply it to practical problems.
Combination immunotherapy of αPD-1 and extended half-life IL-2 clears established GL261 gliomas in an MHC class I independent fashion
Tritz, Zachariah P. , Ayasoufi, Kathy, Malo, Courtney S. , Khadka, Roman H., Yokanovich, Lila T. , Hansen, Michael, Wang, Chensu , Johnson, Aaron J. , Himes, Benjamin , Goddery, Emma N. , Fain, Cori E. , Jin, Fang , Irvine, Darrell J , Wittrup, K Dane , Parney, Ian F. , Johnson, Aaron J

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 169.15-169.15

10.4049/jimmunol.204.supp.169.15 Get It

Abstract Glioblastoma multiforme (GBM) is a deadly CNS malignancy with an average survival of ~12 months post diagnosis despite aggressive treatment. Immunotherapy approaches to treat GBM are being developed, but the unique immune environment of the brain and the immunosuppressive features of GBM have complicated early efforts. Even αPD-1 checkpoint blockade, highly useful in the context of melanoma, has proved ineffective in the treatment of GBM. In order to promote the efficacy of αPD-1 against the GL261 murine model of GBM, we supplemented this therapy with an engineered IL-2 cytokine. IL-2 therapy has been used clinically for metastatic melanoma and renal cancer, but its short half-life in circulation necessitated dangerously high doses to keep the drug concentration sufficiently high. Fusing IL-2 to the mouse serum albumin molecule (MSA-IL-2), extends the cytokine’s half-life. While neither αPD-1 nor MSA-IL-2 are effective monotherapies against the GL261 model tumor, we have found this combination immunotherapy to provide durable tumor clearance and to create immunologic memory capable of resisting GL261 rechallenge. Most strikingly, this combination therapy is independent of the CD8 T cell function, clearing established GL261 tumors in mice incapable of MHC class I restricted antigen presentation. Independence of MHC class I restricted antigen presentation makes this combination immunotherapy using αPD-1 checkpoint blockade both highly novel and translatable to clinical use.
Network-guided bioengineering of oncolytic immunovirotherapies for glioblastoma
Monie, Dileep D. , Ung, Choong Yong , Vile, Richard G. , Monie, Dileep D , Zhang, Cheng , Correia, Cristina , Li, Hu

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 169.17-169.17

10.4049/jimmunol.204.supp.169.17 Get It

Abstract Glioblastoma is the most common and lethal primary brain tumor in adults, with a median survival less than 15 months despite current standard of care. Oncolytic immunovirotherapies (OVs) have shown promise in early clinical trials. OVs are engineered to specifically target cancer cells, trigger autophagic programmed cell death, and release tumor antigens in the context of T-cell activating cytokines. Cellular communication network factor 1 (CCN1) is an extracellular matrix protein expressed in 70% of glioblastomas that has been shown to drastically reduce OV efficacy, particularly herpes simplex virus type 1 (HSV-1). Our objectives were to decode protein-protein interaction (PPI) networks activated by CCN1, identify critical nodes in resistance networks, and use this analysis to design OVs that overcome CCN1-mediated resistance. We used NetDecoder to elucidate phenotype-specific PPI subnetworks in LN229 human glioblastoma cells with tetracycline-inducible CCN1 expression. Publicly available microarray data on CCN1-induced and control samples established differentially expressed genes, which served as sources in our PPI network to derive prioritized context-specific subnetworks. We found that 11 source genes collaborate via 39 deep nodes to confer OV resistance to CCN1-expressing glioblastomas. Of these, a router (IKBKE) and a sink (YBX1) have been previously implicated in glioblastoma pathogenesis. We conclude that autophagy regulator HSP90AA1, a critical node, may be targeted to improve OV efficacy in CCN1-expressing glioblastomas. Furthermore, WebGestalt overrepresentation analysis of subnetwork nodes suggests that oncolytic adenovirus may be more effective than HSV-1 as a synthetic biology chassis.